The questionnaires and method of delivery used in the pilot study were found to be feasible, hence no alterations were made before commencing the main study. Data from the pilot study have been therefore combined with that from the main study in the analyses presented.
The management of pain in patients with cancer has changed considerably in the past 10-20 years. The principles of regular oral administration of analgesics and individualisation of dose (Saunders, 1963) have been widely promoted and increasingly adopted.
Data from hospices and continuing care units in the UK indicate that pain is a major problem in 75% of patients on admission. Yet these specialist centres report figures for unrelieved pain of only 1-10% when the principles of effective pain management are properly applied (Twycross & Lack, 1983) . This suggests that there remain considerable problems in successfully achieving control of pain in cancer patients in non-specialist environments. At the root of this may be continued misunderstanding of, or inappropriate fears about, the strong analgesic drugs likely to be needed in this situation.
A review of medical inpatients with pain from a variety of causes published in 1973 found that 73% of patients had poor control of their pain, with 32% of these reporting severe distress (Marks & Sacher, 1973) . A major contributory factor appeared to be inappropriate and inadequate use of analgesic medication. The study was based on a questionnaire survey of staff physicians in two large New York Hospitals and revealed considerable confusion about the use of strong opioid analgesics. In particular there were exaggerated fears of the dangers of addiction and a tendency to overestimate potency and duration of action.
We have sought to assess prescribing practices for patients with cancer pain among populations of doctors in the United Kingdom. A postal questionnaire was used in order to see whether similar attitudes to those previously reported were still prevalent. 
Data analysis
The questionnaires and method of delivery used in the pilot study were found to be feasible, hence no alterations were made before commencing the main study. Data from the pilot study have been therefore combined with that from the main study in the analyses presented.
In the analysis the study sample has been divided into three groups: specialist oncology hospitals (the two Royal Marsden Hospitals), general hospitals (Manchester Royal Infirmary and Basingstoke District General Hospitals) and general practice.
Disparity between the total number of replies and the totals for individual questions is due to respondents failing to answer certain questions.
Results
The response rate was 62% (36/58) (100%) were chosen by 28% of those qualified for over 20 years compared with only 8% of those qualified for less than 5 years. Both extent of specialist oncology experience and seniority also influenced choice of analgesic. A preference for morphine or diamorphine elixir was related to oncology experience with 52% of those with more than 3 years oncology experience choosing these, compared to 24% of those with no oncology experience. In contrast, MST was chosen by only 30% of those with more than 3 years oncology experience but 56% of those with no oncology experience. The use of weak analgesics was almost exclusively seen in those with less than I year of oncology experience (only four doctors with more than 3 years oncology experience chose weak opioid analgesics).
Two hundred and thirty-one of 248 respondents (93%) indicated that they would administer their drug of first choice regularly, and 17 (7%) 'as required'. Of those who would not give the drug regularly, only six had chosen morphine as their drug of first choice, all of these in the form of MST. The remainder chose buprenorphine (six), an NSAID (two), weak opioid (two), or 'other opioids' (one).
Two hundred and eight of 248 respondents (84%) chose the oral route as their first choice route of administration. Some anomalies between drug of choice and route of choice were seen: 14 chose parenteral administration, but gave an oral preparation as their drug of choice (ten MST, and four an NSAID). Thirteen out of 20 (65%) of those choosing intermittent parenteral injections were from the non-specialist hospitals. Twelve of the 19 who chose a continuous infusion had previous oncology experience, in contrast to five of the 20 who chose intermittent injections.
The preferred frequency of administration was inevitably influenced by the drug of first choice. The results for morphine and diamorphine are shown in Table II . Forty-three (37%) of those who chose MST would administer the drug at less than 12-hourly intervals and of these 19 would give it 6-hourly or more frequently. This group comprised 15 GP's, 23 general hospital doctors and five doctors in the specialist oncology hospital. Six respondents (of these 43) indicated that they would give MST 'as required'.
Thirty-five out of 201 (17%) doctors choosing morphine or diamorphine defined an upper dose limit, and of these 24 had chosen MST as their preferred formulation. Twelve of the 35 indicated a limit of less than 100 mg, 13 between 100 and 199 mg, and nine greater than 200 mg. One respondent stated a maximum dose of six MST tablets, strength unspecified. In contrast, for drugs with a limited therapeutic range (such as buprenorphine, weak opioids, and NSAIDs) 14 of 40 (35%) stated that they would use these drugs with no dose limit.
The questionnaire asked respondents to score the relative importance of five factors influencing drug dosage. Pain severity emerged as by far the most important determinant of dose. The remaining four factors were age, body weight, coexisting chronic lung disease and impaired renal or hepatic function. No particular preference for any of these four factors was seen and no clear trends within sub-groups of the study sample. Table III shows the action which respondents would take if their initial treatment resulted in either an inadequate degree or insufficient duration of analgesia. One hundred and seventy (68%) indicated that an increase in dose would be the appropriate action to take for inadequate degree of analgesia. One hundred and seventy-nine (72%) stated that in order to resolve inadequate duration of analgesia either increasing the dose or the frequency of administration was indicated. Table IV shows the importance respondents placed (Marks & Sachar, 1973 (Yudkin et al., 1987) .
It is important to note that of the 78 respondents in the specialist hospitals group only six were specifically involved in pain control, the remainder working in the departments of medicine, surgery and radiotherapy. Many of these would be junior staff with no special training in or commitment to a career in oncology. In this respect their backgrounds and experience should be similar to the other populations of hospital doctors surveyed. Thus, whilst it is necessary to exercise some caution in attempting to extrapolate the results to the entire study population because of the low response rate, we believe that the data allow valid inferences to be drawn. If the specialist hospital data are taken by themselves they indicate important changes in attitude and knowledge particularly amongst hospital junior staff. Coupled with the data from the other groups of doctors sampled the results give some indications about current practices and also highlight areas which require further emphasis in teaching on cancer pain management. Even in these doctors who were interested and motivated enough to complete the questionnaire there remain some areas of fundamental misunderstanding.
The guidelines published by the World Health Organisation (WHO, 1986) based on clinical experience in specialist units in many countries recommend the use of a simple three step analgesic ladder with morphine as the strong opioid analgesic of choice given orally on a regular 4-hourly basis. In this study, 80% of respondents chose morphine (or diamorphine) as their first choice analgesic, 84% chose the oral route, and 87% indicated that they would administer the analgesic regularly.
Morphine elixir was the formulation of choice in the specialist oncology hospital, but controlled-release morphine tablets (MST) were the preferred form in both other hospitals and in general practice and MST was clearly preferred by those qualified for less than 5 years. Weak opioids or non-opioids were chosen by a small but significant proportion of doctors (who tended to be in the older age groups).
MST was prescribed in regimens varying from once a day to every 2 h. This indicates considerable confusion abut MST. Although awareness of the product is very high, it appears to be subject to widespread misuse. MST is designed for 12-hourly administration and rarely has to be given more frequently (Hanks, 1989 Replies regarding the relative contraindications to the use of strong opioid drugs suggested significant changes in attitude to that commonly cited, where fear of respiratory depression and addiction are held to be important reasons for withholding adequate analgesia (Saunders, 1963; Twycross & Lack, 1983; Marks & Sachar, 1973) . In this study respiratory depression and addiction did not appear to be seen as major contraindications. Prognosis was not considered to be a major determining factor in the use of analgesia, although one quarter of respondents had reservations about the use of strong opioid analgesics in patients with a prognosis of more than 6 months.
In conclusion, the majority of respondents in this study have chosen to use regular morphine or diamorphine given orally, regularly, titrating the dose to pain severity with no arbitrary upper limit for severe pain in patients with cancer. Fears of respiratory depression and addiction and a relatively long prognosis no longer appear to be major deterrents to the use of strong analgesics in the control of chronic severe cancer pain.
The data demonstrate that in a specialist oncology hospital incorporating an active palliative care unit the basic principles of pain control in advanced cancer can be readily applied by the majority of doctors. In the more heterogenous populations of the general hospitals and general practice problems have been demonstrated even within this group of motivated responders, particularly in the use of 'as required' medication by a significant minority and both the choice of MST as the first choice formulation of morphine and its use at dose intervals less than 12-hourly. This emphasises the need for continued efforts in education and research in this important area to disseminate more widely the accepted principles for the management of pain from advanced cancer.
